TY  - JOUR
A1  - Rovituso, Damiano M.
A1  - Duffy, Catharina E.
A1  - Schroeter, Michael
A1  - Kaiser, Claudia C.
A1  - Kleinschnitz, Christoph
A1  - Bayas, Antonios
A1  - Elsner, Rebecca
A1  - Kuerten, Stefanie
T1  - The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
JF  - Scientific Reports
N2  - B cells have only recently begun to attract attention in the immunopathology of multiple sclerosis (MS). Suitable markers for the prediction of treatment success with immunomodulatory drugs are still missing. Here we evaluated the B cell response to brain antigens in n = 34 relapsing-remitting MS (RRMS) patients treated with glatiramer acetate (GA) using the enzyme-linked immunospot technique (ELISPOT). Our data demonstrate that patients can be subdivided into responders that show brain-specific B cell reactivity in the blood and patients without this reactivity. Only in patients that classified as B cell responders, there was a significant positive correlation between treatment duration and the time since last relapse in our study. This correlation was GA-specific because it was absent in a control group that consisted of interferon-\(\beta\) (IFN-\(\beta\))-treated RRMS patients (n = 23). These data suggest that GA has an effect on brain-reactive B cells in a subset of patients and that only this subset benefits from treatment. The detection of brain-reactive B cells is likely to be a suitable tool to identify drug responders.
KW  - cortical pathology
KW  - natural history
KW  - disability
KW  - expression
KW  - antibodies
KW  - disease
KW  - lesions
KW  - trial
KW  - multiple sclerosis
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148172
VL  - 5
IS  - 14265
ER  - 
TY  - JOUR
A1  - Ruck, Tobias
A1  - Bittner, Stefan
A1  - Afzali, Ali Maisam
A1  - Göbel, Kerstin
A1  - Glumm, Sarah
A1  - Kraft, Peter
A1  - Sommer, Claudia
A1  - Kleinschnitz, Christoph
A1  - Preusse, Corinna
A1  - Stenzel, Werner
A1  - Wiendl, Heinz
A1  - Meuth, Sven G.
T1  - The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies
JF  - Oncotarget
N2  - NKG2D is an activating receptor on T cells, which has been implicated in the pathogenesis of autoimmune diseases. T cells are critically involved in idiopathic inflammatory myopathies (IIM) and have been proposed as specific therapeutic targets. However, the mechanisms underlying T cell-mediated progressive muscle destruction in IIM remain to be elucidated. We here determined the involvement of the NKG2D - IL-15 signaling pathway. Primary human myoblasts expressed NKG2D ligands, which were further upregulated upon inflammatory stimuli. In parallel, shedding of the soluble NKG2D ligand MICA (sMICA) decreased upon inflammation potentially diminishing inhibition of NKG2D signaling. Membrane-related expression of IL-15 by myoblasts induced differentiation of naive CD8\(^+\) T cells into highly activated, cytotoxic \(CD8^+NKG2D^{high}\) T cells demonstrating NKG2D-dependent lysis of myoblasts in vitro. \(CD8^+NKG2D^{high}\) T cell frequencies were increased in the peripheral blood of polymyositis (PM) patients and correlated with serum creatinine kinase concentrations, while serum sMICA levels were not significantly changed. In muscle biopsy specimens from PM patients expression of the NKG2D ligand MICA/B was upregulated, IL-15 was expressed by muscle cells, CD68\(^+\) macrophages as well as CD4\(^+\) T cells, and \(CD8^+NKG2D^+\) cells were frequently detected within inflammatory infiltrates arguing for a local signaling circuit in the inflammatory muscle milieu. In conclusion, the NKG2D - IL-15 signaling pathway contributes to progressive muscle destruction in IIM potentially opening new therapeutic avenues.
KW  - MIC ligands
KW  - pathology section
KW  - T cell activation
KW  - idiopathic inflammatory myopathies
KW  - polymyositis
KW  - IL-15
KW  - NKG2D
KW  - receptor
KW  - expression
KW  - lymphokine-activated killer
KW  - human muscle-cells
KW  - multiple sclerosis
KW  - celiac disease
KW  - tumor immunity
KW  - NKG2D ligands
KW  - cutting edge
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136047
VL  - 6
IS  - 41
ER  -